Analysis of risk factors for ventilator-associated pneumonia in patients with acute respiratory distress syndrome and pathogen detection
10.3760/cma.j.cn341190-20240513-00554
- VernacularTitle:ARDS患者并发VAP的危险因素分析及病原菌检测
- Author:
Xinting XU
1
;
Yao ZHANG
;
Bo HAN
;
Chen CUI
;
Lizhan CHEN
Author Information
1. 西安国际医学中心医院呼吸内科，西安 710000
- Keywords:
Respiratory distress syndrome,adult;
Pneumonia,ventilator-associated;
Risk factors;
Serum albumin;
C-reactive protein;
Coma
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(11):1633-1638
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the risk factors and pathogen distribution of ventilator-associated pneumonia (VAP) in patients with acute respiratory distress syndrome (ARDS).Methods:A retrospective analysis was conducted on the clinical data of 118 patients with ARDS who received treatment at Xi'an International Medical Center Hospital from January 2020 to January 2023. The patients were divided into two groups: the VAP group ( n = 38) and the non-VAP group ( n = 80), based on the presence of concurrent VAP. Serological indicators, blood gas analysis parameters, and ventilator settings were compared between the two groups to identify the risk factors associated with the occurrence of VAP. Pathogenic bacteria in the patients' sputum were also detected. Results:Among the 118 patients, there were 79 males and 39 females, with an average age of (53.1 ± 9.6) years. The primary underlying conditions leading to ARDS included chronic obstructive pulmonary disease in 49 cases (41.53%), sepsis in 20 cases (16.95%), severe pneumonia in 17 cases (14.41%), and extensive stroke in 16 cases (13.56%). Univariate analysis revealed that, compared with the non-VAP group, the VAP group had significantly more severe ARDS ( Z = -4.73, P < 0.05). Compared with the non-VAP group, the levels of albumin, platelets, and procalcitonin in the VAP group were significantly lower ( t = 13.75, 3.11, 2.27, all P < 0.05), while levels of high-sensitivity C-reactive protein, transforming growth factor beta (TGF-β), and angiotensin Ⅱin the VAP group were significantly higher ( t = 2.51, 26.63, 27.50, all P < 0.05). The VAP group had a significantly higher proportion of patients who experienced coma, underwent tracheostomy, and received more than two types of antibiotics (χ2 = 14.84, 19.04, 11.22, all P < 0.05). The VAP group also had significantly longer duration of antibiotic use compared with the non-VAP group ( t = 6.88, P < 0.05). Multivariate analysis showed that albumin ( OR = 2.632, 95% CI: 1.398-3.749), high-sensitivity C-reactive protein ( OR = 2.358, 95% CI: 1.534-4.036), coma ( OR = 3.035, 95% CI: 2.034-3.834), and use of more than two types of antibiotics ( OR = 2.005, 95% CI: 1.363-2.846) were independent risk factors for the occurrence of VAP in patients with ARDS (all P < 0.05). In 38 patients with VAP, 63 pathogenic strains were isolated from sputum, while in 80 patients with non-VAP, 128 pathogenic strains were isolated. The most common pathogens identified were Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, and Staphylococcus aureus. In the VAP group, a single pathogen was identified in 16 cases (42.11%), whereas in the non-VAP group, a single pathogen was identified in 51 cases (63.75%). Two types of pathogens were found in 14 cases (36.84%) of the VAP group and 25 cases (31.25%) of the non-VAP group, while three or more pathogens were detected in 8 cases (21.05%) of the VAP group and 4 cases (5.00%) of the non-VAP group. The survival rates for the VAP and non-VAP groups were 57.9% (22/38) and 85.0% (68/80), respectively, with the non-VAP group showing a significantly higher survival rate (χ2 = 22.67, P < 0.001). Conclusion:The risk of VAP in patients with ARDS is high, with two or more pathogen infections being predominant. Clinical interventions should be strengthened.
